Folitixorin is a reduced form of folic acid and a cofactor for thymidylate synthase[1, 2]. Folitixorin is a potential agent for modulating 5-fluorouracil (5-FU) cytotoxicity in adjuvant oncology research[3]. Folitixorin can form a ternary complex with thymidylate synthase and 5-FU, inhibiting thymidylate synthase activity and DNA synthesis[4].
References:
[1] Zarow C, Pellino A M, Danenberg P V. Large-scale and small-scale methods for the preparation of 5, 10-methylenetetrahydrofolate[J]. Preparative Biochemistry & Biotechnology, 1982, 12(5): 381-393.
[2] Shirasaka T, Shimamoto Y, Ohshimo H, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo[J]. Cancer chemotherapy and pharmacology, 1993, 32: 167-172.
[3] Costantini C L, Reid T R, Bouvet M. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer[J]. Hepato-gastroenterology, 2009, 56(91-92): 645-649.
[4] Patel K, Yerram S R, Azad N A, et al. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing[J]. Oncotarget, 2012, 3(7): 678.
Folitixorin是叶酸的一种还原形式，也是胸苷酸合成酶的辅助因子[1, 2]。Folitixorin是一种在辅助肿瘤研究中调节5-氟尿嘧啶（5-FU）细胞毒性的有潜力的试剂[3]。Folitixorin能够与胸苷酸合成酶和5-FU形成三元复合物，抑制胸苷酸合成酶活性和DNA合成[4]。